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 2 
ABSTRACT 28 
 Candida species are a common source of nosocomial bloodstream infections in 29 
critically ill patients. The sensitivity of the traditional diagnostic procedure based on 30 
blood culture is variable and it usually takes two to four days before growth of 31 
Candida species is detected. We developed a four-hour method for the quantification 32 
of Candida species in blood, combining immunomagnetic separation (IMS) with 33 
solid-phase cytometry (SPC) using viability labelling. Additionally, Candida albicans 34 
cells could be identified in real-time by using fluorescent in situ hybridisation. When 35 
analysing spiked blood samples, our method was shown to be sensitive and specific 36 
with a low detection limit (1 cell/ml of blood). In a proof of concept study, we applied 37 
the IMS/SPC method to 16 clinical samples and compared it to traditional blood 38 
culture. Our method proved more sensitive than culture (seven samples were positive 39 
with IMS/SPC but negative with blood culture) and identification results were in 40 
agreement. The IMS/SPC data also suggest that mixed infections might occur 41 
frequently as in five samples C. albicans and at least one other Candida species was 42 
found. Additionally, in two cases, high numbers of cells (175-480 cells/ml of blood) 43 
were associated with an endovascular source of infection.  44 
 45 
Key words: Candidemia, solid-phase cytometry, immunomagnetic separation, rapid 46 
quantification  47 
 3 
INTRODUCTION 48 
Candida species are a common source of nosocomial bloodstream infections in 49 
critically ill patients, with mortality rates exceeding 40%. Rapid detection and 50 
identification of Candida albicans and other Candida species could result in early 51 
initiation of adequate antifungal therapy, an important factor reducing morbidity and 52 
mortality 3, 16 .  53 
At present, the gold standard for the detection of Candida species in the 54 
bloodstream is culture of blood samples. Although blood culture systems have 55 
evolved in recent years from manual to fully automated systems, the diagnostic 56 
sensitivity is still variable and differs greatly among studies, with 40 to 82% of blood 57 
culture bottles spiked with Candida or from patients with proven candidemia showing 58 
positive results 4, 6, 9, 10, 18 . Possible explanations are the low numbers of 59 
Candida cells present in the blood during fungemia (10 - 25 cells per 10 ml of blood) 60 
4, 10, 18 , the use of growth media which are not optimal for fungal growth and the 61 
presence of antimycotics in the blood 6 . Additionally, it usually takes two to four 62 
days before growth of Candida species is detected in blood culture bottles 4, 10 .  63 
 Several studies have shown good results when using PCR on DNA isolated 64 
from whole blood for the detection of candidemia 5, 13, 21, 22 . However, one of the 65 
problems using PCR is the possibility of detecting DNA from dead and/or degrading 66 
yeast cells instead of living yeasts, leading to false-positive results 5, 13, 21, 22 . 67 
Also, in many cases only small sample volumes can be used, or a long and 68 
cumbersome sample preparation is needed to reduce the influence of inhibitors 69 
present in blood 5, 13 . 70 
 Another approach is to recover yeast cells by immunomagnetic separation 71 
(IMS) prior to further analysis. Magnetic beads coated with antibodies are used to 72 
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capture the yeast cells present in the clinical sample and separation occurs in a 73 
magnetic field 15 . Although IMS has been used frequently for the recovery of 74 
specific microorganisms from different samples, the recovery rate of the 75 
microorganisms is rather low 8, 15, 17 . After separation of the cells from the sample 76 
several analysis methods such as plating, PCR and solid-phase cytometry (SPC) can 77 
be used to quantify the number of microorganisms. 78 
 In SPC, the principles of epifluorescence microscopy and flow cytometry are 79 
combined. Microorganisms are retained on a membrane filter, fluorescently labelled 80 
and automatically counted by the Chemscan RDI laser-scanning device. 81 
Subsequently, the data for each fluorescent spot are analysed by a computer to 82 
differentiate between fluorescent microorganisms and particles. Each retained spot 83 
can visually be inspected using an epifluorescence microscope 11, 20 . Due to its low 84 
detection limit, speed and the possible use of taxonomic probes for identification, SPC 85 
has the potential to overcome the shortcomings of other methods for quantification of 86 
Candida species in blood samples 7, 14 . 87 
 In the present study, a method for the rapid quantification of Candida species 88 
and identification of C. albicans in whole blood based on IMS and SPC is described. 89 
This method was optimised using spiked blood samples and subsequently used to 90 
analyse 16 blood samples from high-risk patients. 91 
 92 
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MATERIALS AND METHODS 93 
IMS/SPC method. 30 µl polyclonal anti-C. albicans antibody conjugated with 94 
fluorescein isothiocyanate (FITC) (Acris Antibodies, Herford, Germany) and 30 µl 95 
monoclonal anti-FITC antibody bound to microbeads (Miltenyi Biotec, Bergisch 96 
Gladbach, Germany) was added to an EDTA-treated whole blood sample (max. 97 
volume: 15 ml). After incubation at room temperature for one hour with head-to-tail 98 
rotation, the sample was loaded on a whole blood column (Miltenyi Biotec). Prior to 99 
loading, the column was inserted into a QuadroMACS cell separator (Miltenyi Biotec) 100 
and prewashed with 3 ml of separation buffer (phosphate buffered saline (PBS), 0.5% 101 
bovine serum albumin and 2 mM EDTA, pH 7.2). Afterwards, the column was 102 
washed three times with 3 ml separation buffer, removed from the magnetic field and 103 
the yeasts were eluted with 5 ml elution buffer (Miltenyi Biotec).  104 
The eluate was filtered over a 2.0 µm Cycloblack-coated polyester membrane 105 
filter (AES-Chemunex, Ivry-sur-Seine, France) and filters were incubated at 55°C for 106 
30 min with 100 µl of PNA
Flow
 reagent (AdvanDx, Vedbaek, Denmark) containing a 107 
FITC-conjugated peptide nucleic acid (PNA) probe specific for C. albicans [19]. 108 
Subsequently, filters were incubated with 100 µl Wash Buffer
Flow
 (AdvanDx) for 10 109 
min at 55°C. Finally, tyramide signal amplification was used to obtain red fluorescent 110 
C. albicans cells. To this end, the filter was placed on top of 100 µl polyclonal anti-111 
FITC antibody conjugated with horseradish peroxidase (AbD Serotec, Oxford, UK) 112 
(10 µg/ml PBS) for 30 min at 30°C. A tyramide Alexa Fluor derivative (Invitrogen, 113 
Leek, the Netherlands) was then converted to its red fluorescent form by incubating 114 
the filter on 100 µl tyramide solution (stock solution diluted 1:50 in amplification 115 
buffer) for 30 min at 30°C. Between different steps, filters were rinsed three times 116 
with 1 ml PBS. Finally, all viable microorganisms were fluorescently labelled (green) 117 
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by incubating the filters at 37°C for one hour on a cellulose pad saturated with 600 µl 118 
ChemChrome
 
V6 viability staining solution (stock solution diluted 1:100 in the 119 
labelling buffer ChemSol
 
B2) (AES-Chemunex). With this procedure, all fungal cells 120 
retained on the filter are labelled green.  121 
 The filters with labelled microorganisms were placed on a holder, on top of a 122 
support pad (AES-Chemunex) moistened with 100 µl of Chemsol B2 (AES-123 
Chemunex) and scanned by the ChemScan RDI (AES-Chemunex). This solid-phase 124 
cytometer consists of an argon laser, emitting light of 488 nm and two photomultiplier 125 
tubes, that detect the fluorescent light emitted by the labelled cells. The produced 126 
signals are processed by a PC, applying a series of software discriminants to 127 
differentiate valid signals associated with labelled Candida cells from other 128 
fluorescent particles. Subsequently, results are displayed as green spots on a 129 
membrane filter image in a primary and, after software elimination of background, 130 
secondary scan map 14 . To confirm the results, visual inspection using an Olympus 131 
BX40 epifluorescence microscope (Olympus, Tokyo, Japan) was performed. The 132 
filter holder was placed on a computer-driven moving stage in exactly the same 133 
position as in the Chemscan RDI. Subsequent highlighting of a green spot in the 134 
secondary scan map on the PC resulted in the direction of the microscope to the 135 
respective position on the membrane filter 2, 12 , which allowed rapid visual 136 
inspection of all fluorescent spots. The red fluorescence of C. albicans cells can easily 137 
be observed using a 590 nm cutoff emission filter 20 . 138 
 139 
 Preparation of the spiking solutions. In order to validate the IMS/SPC 140 
procedure, several experiments with spiked blood samples were carried out. An 141 
overview of the fungi used in these experiments is given in Table 1. These fungi were 142 
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cultured overnight at 30°C in Sabouraud liquid medium and serial dilutions were 143 
made in physiological saline. Subsequently, the number of cells was determined by 144 
SPC prior to spiking 20  and one ml of the obtained cell suspensions was used to 145 
spike the blood samples. For all spiking experiments, blood was freshly drawn from 146 
healthy volunteers, maintained at 4°C and used in experiments the same day.  147 
 148 
Evaluation of the sensitivity and specificity of the assay. For sensitivity 149 
testing, the recovery of all Candida species (27 strains) was determined by analysis of 150 
spiked blood samples (10 to 50 Candida cells/10 ml of blood) with IMS/SPC. The 151 
specificity of the antibody for immunomagnetic capture of Candida cells was tested 152 
by spiking blood with various fungi not belonging to the genus Candida (11 strains). 153 
Additionally, the specificity of the PNA probe for identification of C. albicans was 154 
examined using all other Candida strains (16 strains) (Table 1).  155 
 156 
Determination of the detection limit. In order to determine the detection limit 157 
of the IMS/SPC assay, a suspension of C. albicans ATCC MYA-2876 (76 cells/ml as 158 
determined by SPC) was serially diluted (6 times) and the number of cells present in 159 
these dilutions was also determined by SPC. Subsequently, blood samples from 160 
healthy volunteers were spiked with one ml of these solutions and the recovery with 161 
the IMS/SPC procedure was determined. 162 
 163 
Comparison of IMS/SPC with blood culture (spiked blood). In order to 164 
compare the IMS/SPC method with conventional blood culture, five whole blood 165 
samples (10 ml) were obtained from ten healthy volunteers. One unspiked sample per 166 
healthy volunteer was used as a negative control and was analysed with the IMS/SPC 167 
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assay simultaneously with the other samples. Two samples per volunteer were spiked 168 
with C. albicans ATCC MYA-2876 and the other two were spiked with C. 169 
dubliniensis IHEM 14280, C. glabrata MUCL 29833, C. krusei IHEM 1795, C. 170 
parapsilosis IHEM 3270 or C. tropicalis MUCL 29952. The whole blood samples 171 
were spiked with 1 to 100 Candida cells. Two spiked whole blood samples were 172 
analysed immediately by IMS/SPC and two were analysed by conventional blood 173 
culture. To that end, the latter two spiked blood samples were aseptically introduced 174 
into a BacT/ALERT FA blood culture bottle (Biomérieux, Marcy l'Etoile, France) and 175 
the bottle was incubated at 37°C. The change of the color of the indicator was 176 
monitored visually.  177 
 178 
Storage of blood samples. In order to investigate if storage of the blood 179 
samples at 4°C has an influence on the viability of the Candida cells, analysis was 180 
performed immediately and three, six, nine, 16 and 24 h after spiking. To that end, 181 
two times six blood samples (5 ml) from a healthy volunteer were spiked with 24 or 182 
76 C. albicans ATCC MYA-2876 cells (cell number determined by SPC) and stored 183 
at 4°C until analysis.  184 
 185 
Proof of concept by analysis of clinical samples. Finally, 16 samples from 15 186 
patients with candidemia or suspected candidemia were analysed (Table 2). This 187 
research was approved by the ethical comitee of University Hospitals Leuven 188 
(Belgium) (study number S51459). Blood samples were stored at 4°C until analysis 189 
and all samples were analysed within 24 h of collection (Table 2). An equal aliquot of 190 
the blood sample was analysed both by the IMS/SPC procedure and by using a 191 
BacT/ALERT FA blood culture bottle that was monitored visually. If the blood 192 
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culture was positive, a subculture on Chromagar (BD) was made and subsequent 193 
identification of all yeasts recovered was performed using the API-20C AUX system 194 
(Biomérieux).  195 
 10 
RESULTS 196 
Evaluation of the sensitivity and specificity of the assay. The sensitivity of 197 
the assay was confirmed as for all Candida strains tested, the average recovery (± 198 
standard deviation) was 114% (± 20%) (n=27) after IMS/SPC analysis. The method 199 
proved highly specific and only cells belonging to Candida species were retained 200 
using the IMS procedure (Table 1). The specificity of the PNA probe was confirmed 201 
as only C. albicans cells yielded red fluorescence (Table 1).  202 
 203 
Determination of the detection limit. A linear correlation between the number 204 
of cells (ranging from 0 to 76 as determined with SPC prior to spiking) in the spiking 205 
solutions and the number of cells found in the blood samples supplemented with this 206 
solution was obtained (data not shown). The average recovery (± standard deviation) 207 
was 116% (± 18%), and the detection limit was one cell per 10 ml of blood. 208 
 209 
 Comparison of IMS/SPC with blood culture (spiked blood). In order to 210 
compare the results obtained with IMS/SPC and conventional blood culture, we 211 
analysed spiked blood samples of ten healthy volunteers in parallel. The average 212 
recovery of Candida cells with the IMS/SPC procedure was 95% ± 29% (n=20) and 213 
was independent of the species. The absolute differences in number of cells in the 214 
spiking solutions and blood samples analysed by IMS/SPC were very small (Fig. 1). 215 
No Candida cells were detected in any of the negative control samples. A visual color 216 
change of the CO2 sensor in all blood culture bottles was seen within 25 hours.  217 
 218 
Storage of blood samples. We also determined whether storage (4°C) of blood 219 
samples had an influence on the number of yeast cells detected and could not observe 220 
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a reduction in the number of cells when the sample was analysed within nine hours of 221 
storage (Fig. 2). However, a marked decline (as high as 75%) in the number of cells, 222 
(independent of the absolute number) was found after 16 hours of storage (Fig. 2).  223 
 224 
Proof of concept by analysis of clinical samples. Sixteen clinical samples 225 
were analysed with IMS/SPC and blood culture. Three samples were negative with 226 
both methods, six were positive with both methods and seven were positive with 227 
IMS/SPC but negative with blood culture. For some samples, visual and automated 228 
detection of a change in color of the indicator on the bottom of the blood culture 229 
bottle was compared and the same result was obtained (data not shown). Additionally, 230 
upon subculture, no Candida cells were isolated from any of the negative blood 231 
culture bottles. 232 
Absolute counts obtained with IMS/SPC ranged from 2 to 480 Candida cells 233 
per ml (Table 2). For two patients, an extremely high number of Candida cells was 234 
found in the blood sample (> 175/ml for patient C and 480/ml for patient F). In both 235 
cases, a contaminated catheter was removed after collection of the sample. For patient 236 
C, a follow-up sample was obtained nine days after removal of the catheter and the 237 
start of anidulafungin treatment. This sample contained less cells (IMS/SPC analysis: 238 
2 cells/ml) and was no longer positive with blood culture (Table 2). 239 
The differentiation between C. albicans and other Candida species obtained 240 
with IMS/SPC was in agreement with the results obtained with culture for the six 241 
samples which were positive with both methods (Table 2). For the clinical samples 242 
negative with blood culture in this study and positive with IMS/SPC, the 243 
differentiation between C. albicans and other Candida species obtained with the 244 
IMS/SPC assay, was in agreement with the identity of the isolate recovered before 245 
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inclusion in the present study. Patients A, E, K, M and N presented with a mixed 246 
infection according to the IMS/SPC analysis while this was not observed using the 247 
culture-based method (Table 1). For patient I, C. glabrata and C. albicans were 248 
isolated from a blood culture three days before inclusion in our study. With IMS/SPC 249 
only C. albicans cells were found in the sample. 250 
 251 
 13 
DISCUSSION 252 
 We report the development of a four-hour method for the quantification of 253 
Candida species in blood, based on IMS and SPC using viability staining and 254 
fluorescent in situ hybridisation (FISH) to label all Candida species and C. albicans, 255 
respectively. Analysis of spiked blood samples indicated that our method is specific, 256 
has a low detection limit and allows accurate quantification.  257 
 Using spiked blood samples we did not observe an improved diagnostic 258 
sensitivity with the IMS/SPC method. Unlike in numerous reports in literature, all 259 
blood cultures of spiked samples were positive 4, 10, 18 . This can be explained by 260 
the use of laboratory strains to spike the blood cultures. However, seven clinical 261 
samples were positive with IMS/SPC but negative with blood culture. The latter 262 
observation clearly indicates that the IMS/SPC assay has a higher diagnostic 263 
sensitivity than blood culture. For four of the samples for which blood culture was 264 
negative but IMS/SPC was positive, treatment with antifungal drugs prior to 265 
collection might be an explanation for the divergent results (Table 2).  266 
 We observed that analysis of blood samples within nine hours of sample 267 
collection is recommended due to a reduction in the number of yeast cells recovered, 268 
after longer storage. Nevertheless, even for samples that were analysed more than 9 h 269 
past sampling (Table 2), we were able to quantify the Candida species cells present, 270 
although it is likely that the number observed is an underestimation of the number of 271 
cells actually present at the time of sampling.  272 
 The IMS/SPC method does not only allow the rapid diagnosis of candidemia 273 
but also the accurate quantification of Candida cells. This might help in assessing the 274 
response to antifungal therapy or may lead to the decision to remove intravascular 275 
devices 18 . Our data suggest that a high number of Candida cells present in a blood 276 
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sample is associated with a contaminated intravascular device 18 , although only two 277 
samples were investigated and further research is required to support this hypothesis.  278 
 The present study also demonstrates that mixed infections might occur more 279 
frequently than generally assumed from culture-based techniques. While in five of the 280 
16 clinical samples C. albicans and at least one other Candida species was found 281 
using the IMS/SPC procedure, not a single mixed infection was identified using blood 282 
culture.  283 
 284 
 Only one previous study has used IMS for the recovery of Candida cells from 285 
spiked blood [1]. However, this study used culture after capture of the cells and 286 
therefore results were only obtained one day before results could normally be 287 
obtained with blood culture. Additionally, identification of the Candida species was 288 
only possible after culture and some species were not captured by the antibody. 289 
Finally, the low recovery (11 to 43%) observed for spiked blood samples was a 290 
crucial problem limiting the use of the method for the analysis of clinical samples 291 
containing low numbers of Candida cells [1].  292 
 Several research groups have obtained good results when using PCR on DNA 293 
isolated from blood for the diagnosis of candidemia 5, 13, 22 . The time to result 294 
using a commercial real-time PCR assay (SeptiFast by Roche) is six hours which is 295 
comparable with our method. However, one of the problems of PCR methods is the 296 
possible detection of DNA from dead and/or degrading cells instead of living yeasts. 297 
To avoid this, a labelling step using the viability stain Chemchrome V6 was included 298 
in the SPC procedure described in the present study. 299 
 PNA FISH methods are increasingly being used in hospitals for the 300 
identification of Candida species after the detection of yeasts in blood culture bottles. 301 
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In our study, we used a commercially available PNA probe for C. albicans 302 
identification but by using IMS and SPC we could omit the time-consuming culture 303 
step 19 . The implementation of additional PNA probes allowing the identification of 304 
other Candida species might further improve our method.  305 
 In conclusion, our study provides a proof of principle for the diagnostic 306 
potential of IMS combined with SPC for the detection of Candida cells in whole 307 
blood. In its current form, the method may be too laborious for implementation in a 308 
routine diagnostic laboratory. Further automation of the technique combined with an 309 
expansion of the panel of pathogens that can be detected and identified in blood could 310 
make this technique more attractive for diagnostic laboratories in the future. 311 
 312 
 313 
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Table 1: Overview of the fungi used for sensitivity and specificity testing and their 403 
reactivity with the capturing antibody and the PNA probe used in the assay. 404 
Species Strain designation 
a
 
Reactivity with the 
antibody used for 
immunomagnetic 
capture 
Reactivity with the 
PNA probe used for 
identification of C. 
albicans 
Candida albicans  ATCC MYA-682 + + 
 ATCC MYA-2876 + + 
 ATCC 10231 + + 
 IHEM 9559 + + 
 IHEM 10284 + + 
 MUCL 29903 + + 
 MUCL 29800 + + 
 MUCL 29919 + + 
 MUCL 29981 + + 
 MUCL 30112 + + 
 NCYC 1467 + + 
    
Candida dubliniensis IHEM 14280 + - 
Candida famata CI + - 
Candida glabrata MUCL 15664 
 
+ - 
 MUCL 29833 + - 
Candida guilliermondii CI + - 
Candida inconspicua CI + - 
Candida kefyr CI + - 
Candida krusei IHEM 1796 + - 
Candida lusitaniae CI + - 
Candida maris CI + - 
Candida parapsilosis IHEM 3270 + - 
Candida pseudotropicalis CI + - 
Candida tropicalis IHEM 4222 
IHE% 
+ - 
 IHEM 4225 + - 
 MUCL 29952 + - 
 MUCL 30002 + - 
    
Aspergillus flavus IHEM 2700 - - 
Aspergillus fumigatus IHEM 3768 - - 
Cryptococcus neoformans IHEM 14513 - - 
Fusarium graminearum IHEM 2994 - - 
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Fusarium oxysporum IHEM 14513 - - 
Fusarium solani IHEM 6743 - - 
Penicillium chrysogenum IHEM 3035 - - 
Penicillium simplicissimum IHEM 1202 - - 
Pseudallescheria boydii CBS 101.22 - - 
Saccharmyces cerevisiae ATCC 9763 - - 
Scedosporium prolificans CBS 467.74 - - 
a 
ATCC: American Type Culture Collection; CBS: Centraalbureau voor 405 
Schimmelcultures (the Netherlands); CI: clinical isolate from our own collection; 406 
IHEM: Instituut voor Hygiene en Epidemiologie (Belgium); MUCL: Mycothèque de 407 
l’ Université Catholique de Louvain (Belgium); NCYC: National Collection of Yeast 408 
Cultures (UK). 409 
 410 
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Table 2: Overview of the characteristics of the clinical samples included in the study and the results obtained after analysis with a traditional 411 
blood culture and with the method combining immunomagnetic separation and solid-phase cytometry (IMS/SPC). 412 
Patient 
Blood culture result 
obtained before inclusion 
in this study 
Sample 
collection 
date 
Analysis 
date 
Treatment 
prior to sample 
collection 
Results of the analysis of the clinical samples 
Blood culture 
 
Number of cells/ml of blood 
(IMS/SPC) 
 
C. 
albicans 
other Candida 
spp. 
A -
a
 06-16-09 06-16-09 -
b
 negative  3 3 
B C. glabrata  08-10-09 08-11-09 Fluconazole negative  0 2 
C C. tropicalis  08-11-09 08-12-09 Fluconazole C. tropicalis  0 > 175
c
 
C -
a
 08-20-09 08-20-09 Fluconazole & 
anidulafungin 
negative  0 2 
D C. albicans  08-20-09 08-20-09 Fluconazole negative  3 0 
E C. glabrata  08-20-09 08-21-09 -
b
 C. glabrata  3 4 
F C. glabrata  08-20-09 08-21-09 Fluconazole & 
caspofungin 
C. glabrata  0 480 
G C. albicans  09-14-09 09-15-09 Fluconazole negative  0 0 
H C. tropicalis  09-14-09 09-15-09 Fluconazole negative  0 0 
I C. albicans  09-14-09 09-15-09 Fluconazole C. albicans  2 0 
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C. glabrata 
J C. glabrata  10-06-09 10-07-09 -
b
 C. glabrata  0 4 
K C. glabrata  10-07-09 10-08-09 -
b
 negative  6 3 
L -
a
 10-07-09 10-08-09 -
b
 negative  0 0 
M C. parapsilosis 10-08-09 10-09-09 Fluconazole negative  1 6 
N C. albicans 12-04-09 12-05-09 Fluconazole C. albicans  1 1 
O C. krusei 01-04-10 01-05-10 Caspofungin negative    
a 
No positive blood culture was obtained prior to inclusion in this study. 413 
b 
Patients did not receive treatment prior to inclusion in this study. 414 
c
 Of this blood sample 4 ml was filtered and more than 700 Candida cells were present on the filter but a reliable quantification was impossible. 415 
Filtration of a smaller volume could have led to a more reliable quantification. 416 
 417 
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Figure legends: 418 
Fig. 1: Numbers of Candida cells in the spiking solution (white bars) compared to the 419 
numbers obtained after application of the IMS/SPC procedure on spiked blood 420 
samples of ten healthy volunteers (grey bars).  421 
Fig. 2: The number of C. albicans cells obtained with the IMS/SPC procedure for two 422 
spiked blood samples from one healthy volunteer (triangles and squares respectively) 423 
determined at different time-points during storage of the samples at 4°C. 424 
 425 
 426 
